3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Gastrointestinal
1
Conditions
Melanoma
1
Carcinoma, Basal Cell
1
Interventions
Nivolumab
114
Ipilimumab
114
pembrolizumab
108
aldesleukin
76
Cyclophosphamide
70
fludarabine phosphate
51
Interleukin-2
48
Temozolomide
41
Dacarbazine
36
trametinib
33
dabrafenib
30
Bevacizumab
30
sargramostim
29
Radiotherapy
29
incomplete Freund's adjuvant
27
fludarabine
27
Vemurafenib
25
Radiosurgery
25
Carboplatin
25
Paclitaxel
23
binimetinib
22
Biopsy
22
CTLA-4 Antigen
21
Peripheral Blood Stem Cell Transplantation
20
encorafenib
19
cemiplimab
19
atezolizumab
19
Mycophenolic Acid
19
HhAntag691
19
Aminolevulinic Acid
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
BO-112
×
Dermatologic
×
Clear all
NCT06422936
2026-01-26
SPOTLIGHT204
Highlight Therapeutics
Phase 2
Active not recruiting
60 enrolled
NCT04570332
2025-11-26
SPOTLIGHT203
Highlight Therapeutics
Phase 2
Completed
42 enrolled
12 charts